Name: 2nd Annual MarketsandMarkets ImmunoBio Series
Start: 2024-10-14
End: 2024-10-15
Location: Dorint Thermenhotel- Gesundheitsresort Freiburg

WHAT TO EXPECT

Preclinical and Translational Immuno-Oncology Developments
Biomarker Discovery Techniques: Explore novel strategies, including genomics, proteomics, metabolomics, and bioinformatics, to identify cutting-edge biomarkers in oncology.
Precision Medicine Tailoring: Understand the pivotal role of biomarkers in customizing immunotherapy for individual patients, enhancing efficacy, and minimizing side effects.
Personalizing Cancer Treatment- Challenges and Opportunities
Rigorous Biomarker Validation: Learn strategies and overcome challenges in validating biomarkers for clinical use, ensuring robust and reliable results.
Bioinformatics and AI Analysis: Attend sessions on biomarker data analysis, employing machine learning and artificial intelligence approaches for comprehensive insights.
Biomarker-Based Cancer Diagnostics Development: Gain insights into the development and commercialization of diagnostic tests and platforms based on biomarkers.
Next Gen Antibodies and Targeted Therapies
Immune Checkpoint Inhibitors and Combination Therapies
Tumor Microenvironment and Cancer Biomarkers
CAR-T cell therapy, T Cell Therapy, Adoptive Cell Therapy
Cancer Vaccines and Cancer Microbiome
Collaboration for Advancement: Explore sessions on fostering collaboration among academia, industry, and government agencies to drive biomarker research forward.

Cutting-Edge Insights: Access the latest advancements in biomarker discovery, precision medicine, and clinical applications spanning cancer and immunology.
Innovative Immunotherapy: Dive into immune-oncology projects, exploring antibodies, cellular therapy, and immune checkpoint research. Contribute to interactive discussions, share your work, and stay updated on cutting-edge technologies and platforms.
Networking and Collaboration: Connect with industry leaders, researchers, and peers. Foster collaborations, engage in thought-provoking discussions, and explore partnership opportunities.
Professional Development: Enhance your skills with workshops on cancer biomarker data analysis, machine learning, and artificial intelligence applications. Learn best practices and methodologies for biomarker and IO research.
Practical Applications: Discover how research translates into real-world applications. Explore exhibitor showcases, demonstrations, and case studies, gaining insights into the latest tools and technologies.
Personal and Industry Growth: Step out of your comfort zone, engage in interactive roundtables, and contribute to key discussions. Elevate your personal and professional growth within the dynamic fields of biomarker research and immunotherapy.

Engage in groundbreaking research, expand your network, and drive innovation at the Immunobio Series, where science meets collaboration.

CONFERENCE AGENDA

Registration	08:15 - 08:50
Welcome note from MarketsandMarkets	08:50 - 08:55
Opening Remarks from the Chairperson Philip Arlen, MD, President and CEO, Precision Biologics, Inc	08:55 - 09:00
REDEFINING CANCER IMMUNOTHERAPY: FROM TUMOR MICROENVIRONMENT MODULATION TO IMMUNOGENIC THERAPIES AND BIOMARKER INNOVATIONS
Keynote Presentation - Unveiling Tumor Microenvironment Resistance Targets with the iOTarg Screening Platform - Featuring IOMX-0675, a LILRB1 and LILRB2 Cross-Specific Dual-Targeting Antibody Adriana Turqueti Neves, Associate Director, iOmx Therapeutics AG	09:00 - 09:30
Enhanced Biomarker Discovery and Validation Using TMT® Proteomics Illip Burmester, Technical and Applications Manager, Proteome Sciences	09:30 - 10:00
Novel drug-resistant mouse models for Immuno-Oncology research Jianming Xu, Director, InVivo Pharmacology, GemPharmatech	10:00 - 10:30
Morning Refreshments and Poster Presentation \| One-to-One Networking Meetings	10:30 - 11:15
HLA-I and HLA-II Immunopeptidome Profiling and its use in Studies from Discovery to Clinic Anamarija Pfeiffer, Senior Scientific Project Manager, Biognosys	11:15 - 11:45
Targeting Dendritic Cells to make Cancer Cell Death Immunogenic Raj Mehta, Chief Executive Officer, Adendra Therapeutics Ltd	11:45 - 12:15
Arenavirus-based immuno-virotherapy: efficacious anti-tumor activity combined with advantageous effects on the tumor microenvironment (TME) Dr. Jörg Vollmer, CSO, Managing Director, Abalos Therapeutics GmbH	12:15 - 12:45
Computational pathology: Revolutionizing diagnostics and clearing the way for precision medicine in oncology Philipp Wortmann, Director, Translational Science, Astrazeneca	12:45 - 13:15
Lunch and Poster Presentation \| One-to-One Networking Meetings	13:15 - 14:15
UNVEILING PROGRESS IN IMMUNE CHECKPOINTS, QTCR PLATFORMS, AND CAR T-CELL STRATEGIES
Immune checkpoint inhibitors: insights and advances from CRO perspective Holger Weber, Head of In Vivo Pharmacology, Reaction Biology Europe GmbH	14:15 - 14:45
Seqalis’ qTCR seq platform, an unbiased and quantitative enabling platform to unlock the immune repertoire diversity Jean-Luc Henrioul, Chief Operating Officer, Seqalis	14:45 - 15:15
Leveraging a Novel Non-Gene Edited Platform to Improve Efficacy and Safety of CAR T-Cell Therapies Marine Blackman, Research Scientist, Celyad Oncology	15:15 - 15:45
Afternoon Refreshments and Poster Presentation \| One-to-One Networking Meetings	15:45 - 16:30
New class of Antigen-specific Cancer Active Immunotherapies based on an off-the-shelf Antigen Presenting Cell line (PDCline) Eric Halioua,* President & Chief Executive Officer, PDC*line pharma SA	16:30 - 17:00
Closing Remarks from the Chairperson Philip Arlen, MD, President and CEO, Precision Biologics, Inc	17:00 - 17:05

Registration	08:15 - 08:50
Welcome note from MarketsandMarkets	08:50 - 08:55
Opening Remarks from the Chairperson Daniel Crowley, CEO, RemedyBio	08:55 - 09:00
INNOVATIVE STRATEGIES IN IMMUNOTHERAPY AND BIOMARKERS DEVELOPMENT
Keynote Presentation - Neuropilin-1 (NRP1) as novel target for antisense oligonucleotides (ASOs) to treat patients with solid tumors Andre Maaske, Research Scientist, Secarna	09:00 - 09:30
Translational Genomics: An Overview Of Different Sequencing Strategies In Using Single-Cell Data Analysis Rick Kamps, NGS Manager, Maastricht University	09:30 - 10:00
Ultrasensitive ISP assays for high quality spatial insights. Angela Vasaturo , Director of Scientific Affairs, Ultivue	10:00 - 10:30
Morning Refreshments and Poster Presentation \| One-to-One Networking Meetings	10:30 - 11:15
Deciphering immune function in cancer by mass-scale single cell biology Daniel Crowley, CEO, RemedyBio	11:15 - 11:45
Validation of melanoma non-responders fingerprint fit, to the mechanism of action JJP-1008. Tomasz Grabowski, Head of Preclinical Development, JJP Biologics	11:45 - 12:15
Delving into the Mechanism of Action of Neoantigen Antibodies to Aid the Development of Highly Effective Combination Strategy Towards More Successful Therapies Philip Arlen, MD, President and CEO, Precision Biologics, Inc	12:15 - 12:45
Predicting Patient Response to Checkpoint Inhibitors Jens Kringelum, VP, AI & Innovation, Evaxion Biotech	12:45 - 13:15
Lunch and Poster Presentation \| One-to-One Networking Meetings	13:15 - 14:15
LATEST DEVELOPMENTS & TRENDS IN IO & BIOMARKER RESEARCH
Resistance of cancer in the context of mAbs MOA. Is the next ICIs just a rabbit chase Tomasz Grabowski, Head of Preclinical Development, JJP Biologics Jianming Xu, Director, InVivo Pharmacology, GemPharmatech Adriana Turqueti Neves, Associate Director, iOmx Therapeutics AG Philip Arlen, MD, President and CEO, Precision Biologics, Inc	14:15 - 14:45
Closing Remarks from the Chairperson	14:45 - 14:45